CAS: 129497-78-5; (4R,4As)-Rel-18-Ethenyl-4,4A-Dihydro-3,4-Bis(Methoxycarbonyl)-4A,8,14,19-Tetramethyl-24H,26H-Benzo[b]Porphine-9,13-Dipropanoic Acid Monomethyl Ester

该化合物是一种光敏剂,主要用于光动疗法,特别是用于治疗与年龄有关的肌肉畸形和某些类型的癌症;它是一种在有机溶剂中溶解但水溶性有限的黑绿对黑粉粉,其特点是,它能够在光点激活时产生活性氧物种,从而导致目标地区局部组织破坏;Verteporfin有一种分子配方,包括碳,氢,氮和氧,反映其复杂的结构;它的行动机制包括吸收特定的光波长,它触发光化学反应,损害细胞组成部分,最终导致细胞死亡;由于对光敏度的敏感度,使用脊椎素治疗的病人在治疗后需要一段时间避免直接阳光,以防止皮肤反应;

英文名称(4R,4As)-Rel-18-Ethenyl-4,4A-Dihydro-3,4-Bis(Methoxycarbonyl)-4A,8,14,19-Tetramethyl-24H,26H-Benzo[b]Porphine-9,13-Dipropanoic Acid Monomethyl Ester
中文名称维替泊芬
IUPAC名称(4R,4aS)-rel-18-Ethenyl-4,4a-dihydro-3,4-bis(methoxycarbonyl)-4a,8,14,19-tetramethyl-24H,26H-Benzo[b]porphine-9,13-dipropanoic acid monomethyl ester
其它别名trans-3,4-Dicarboxy-4,4a-dihydro-4a,8,14,19-tetramethyl-18-vinyl-23H,25H-benzo(b)porphine-9,13-dipropionic acid 3,4,9-trimethyl ester
CAS编号129497-78-5
MFCD编号:MFCD28098202
EINECS号:893-418-5
FDA UNII编号:WU713D62N9
分子式:C82H84N8O16
分子量:1437.61
产品CID: 455618
产品分类原料药 → 专科用药 → 眼科用药

相似结构搜索
InChIKey: NJLRKAMQPVVOIU-MJIQIJLISA-N
YHNBVDZVUQFVLS-RDSGBMLISA-N…
计算化学: 氢键受体数24.0氢键供体数6.0可旋转键数24.0

物理性质

沸点°Cat760mmHg
闪点°C
PSA:337.48
LogP:10.246
溶解性DMSO: Soluble2mg/mL, Clear (Warmed)
外观形态黑色粉末
储存条件-20°C
产品应用该化合物用作治疗与湿龄有关的肌肉畸形(AMD),病原性近视和眼顶质血浆综合症(OCELOMISMISIS)引起的亚泡沫酸甲酯新血管化(CNV)的第二代草药素基光素,可导致逐渐或严重视力丧失.在使用无热激光光照射689纳米波长时,脊椎素素在氧存在时产生活性氧物种(特别是单氧),导致局部血管隔热,内向性损伤和有选择地破坏异常的新血管组织,同时避免周围健康的视网膜结构. 快速增生细胞(如铬化新血管内皮囊细胞)选择性地吸收这种物质,由低密度的低密度脂质(LDL)受体(LLD)受试者进行调节,这些细胞中过度表达.

MSDS等安全信息

GHS象形图
GHS符号GHS08 & GHS07;
注释: Health hazard & Exclamation mark
危险类别特定目标器官毒性-重复接触类别2
严重眼刺激类别2
警示词Warning(警告)
危险描述H373 |长期或反复接触可能损害器官.
H319 |造成严重眼刺激.
防范说明P280-P305+P351+P338
UN编号NONH for all modes of transport
WGK Germany3

欧盟法规

C&L通报

合成工艺路线路线简述

海关参考信息

2901210000-乙烯
2901220000-丙烯
2901241000-1,3-丁二烯
2905121000-正丙醇
💡 提示：海关信息按照顺序优先匹配，如需确认的海关信息，请参考相关资料。
详情请参考：📖 海关编码查询和海关进出口税则

专利信息

专利号:US-10676487-B2
优先权日:2015-09-09
标题 :Synthesis and composition of photodynamic therapeutic agents for the targeted treatment of cancer
发明人：KULARATNE SUMITH A; GAGARE PRAVIN; MYERS CARRIE H
权利人:ON TARGET LABORATORIES LLC
摘要:The present invention describes new compounds that are useful for image-guided surgery and photodynamic therapy. In particular the compounds may be targeted to the nucleus or the mitochondria after compounds were delivered to diseased tissues such as cancer using a ligand that target receptor that express on the diseased tissue and followed by receptor mediated endocytosis and provide effective activity against cancer cells as well as other disorders. Methods and compositions for use of the same are described.

专利号:EP-3347010-A1
优先权日:2015-09-09
标题:Synthesis and composition of photodynamic therapeutic agents for the targeted treatment of cancer

专利号:CN-108135885-A
优先权日:2015-09-09
标题 :Synthesis and composition of photodynamic therapy agents for targeted treatment of cancer

专利号:US-2017145035-A1
优先权日:2015-09-09
标题 :Synthesis and composition of photodynamic therapeutic agents for the targeted treatment of cancer

专利号:AU-2016318606-A1
优先权日:2015-09-09
标题 :Synthesis and composition of photodynamic therapeutic agents for the targeted treatment of cancer

专利号:CA-2996307-A1
优先权日:2015-09-09
标题 :Synthesis and composition of photodynamic therapeutic agents for the targeted treatment of cancer

其他信息查阅

台州市科瑞生物技术有限公司

网址: http://www.pharm-intermediates.com
企业联系电话：0576-88813233👤
地址:台州市开发大道东段288号

⚠️ 未注册 · 未认证企业

备注: 📌 数据来源说明：本展台内容基于各搜索引擎等公开数据整理，仅作展示用途。请用户自行辨别
✉️ 若企业需抹除展台内容或有异议，请通过页面底部联系方式告知我们，我们会尽快处理。

上海先辉医药科技有限公司

网址: http://www.pharmprep.cn
电话: 021-67792654👤

⚠️ 未注册 · 未认证企业

备注: 📌 数据来源说明：本展台内容基于各搜索引擎等公开数据整理，仅作展示用途。请用户自行辨别 ✉️ 若企业需抹除展台内容或有异议，请通过页面底部联系方式告知我们，我们会尽快处理。

第 1 / 1 页

现货

供应商参考报价(招募中)

品牌试剂参考报价(招募中)

实用工具

📌 第三方产品分析报告

✅ COA系统入驻 | 共享模式

主要参考文献

1: Tan Q, Xiang C, Zhang H, Yuan Y, Gong S, Zheng Z, Wang X, Liu X, Chen Y, Tan C. YAP promotes fibrosis by regulating macrophage to myofibroblast transdifferentiation and M2 polarization in chronic pancreatitis. Int Immunopharmacol. 2025 Jan 15;148:114087. doi: 10.1016/j.intimp.2025.114087. Epub ahead of print. 67(1719):1-5. doi: 10.58347/tml.2025.1719a. 22(2):460-472. doi: 10.7150/ijms.99062.
5: Shan AP, Hlaing KS, Leelahavanichkul A, Amornphimoltham P. Efficacy of metformin and verteporfin treatment alone or in combination in a murine head and neck cancer xenograft model. Eur J Oral Sci. 2025 Jan
8:e13034. doi: 10.1111/eos.13034. Epub ahead of print.

合成参考文献

参考文献:10.1126/science.1205216
摘要:Yuan J, Cheng KC, Johnson RL, Huang R, Pattaradilokrat S, Liu A, Guha R, Fidock DA, Inglese J, Wellems TE, Austin CP, Su XZ. Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets. Science. 2011 Aug 05;333(6043):724–9.